Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-519 with Statins in Dyslipidemia
NCT02977065Phase 2Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Mar 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rocacetrapib in dyslipidemia (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Percentage change from baseline in Low Density Lipoprotein Cholesterol at 4 weeks. Started Mar 2017; status: completed.
02
Drugs
rocacetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02977065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977065.